Park Avenue Securities LLC purchased a new position in Avantor, Inc. (NYSE:AVTR – Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 10,299 shares of the company’s stock, valued at approximately $139,000.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Rise Advisors LLC bought a new position in Avantor in the 1st quarter valued at approximately $25,000. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Avantor by 288.4% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 1,701 shares of the company’s stock valued at $28,000 after buying an additional 1,263 shares during the period. Wealthquest Corp purchased a new stake in shares of Avantor in the 1st quarter worth $34,000. GAMMA Investing LLC increased its stake in shares of Avantor by 121.6% in the 1st quarter. GAMMA Investing LLC now owns 3,747 shares of the company’s stock worth $61,000 after purchasing an additional 2,056 shares in the last quarter. Finally, Fifth Third Bancorp increased its stake in shares of Avantor by 52.0% in the 1st quarter. Fifth Third Bancorp now owns 3,972 shares of the company’s stock worth $64,000 after purchasing an additional 1,359 shares in the last quarter. 95.08% of the stock is owned by institutional investors.
Avantor Stock Up 0.9%
Shares of NYSE:AVTR opened at $13.80 on Friday. The company has a current ratio of 0.98, a quick ratio of 0.67 and a debt-to-equity ratio of 0.48. Avantor, Inc. has a 12 month low of $10.82 and a 12 month high of $26.14. The company has a 50-day moving average price of $12.75 and a 200 day moving average price of $13.55. The company has a market cap of $9.41 billion, a price-to-earnings ratio of 13.94, a PEG ratio of 4.40 and a beta of 0.98.
Insider Activity at Avantor
In related news, CAO Steven W. Eck sold 3,476 shares of the stock in a transaction dated Tuesday, August 5th. The shares were sold at an average price of $11.39, for a total value of $39,591.64. Following the completion of the transaction, the chief accounting officer owned 55,068 shares of the company’s stock, valued at approximately $627,224.52. This trade represents a 5.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.20% of the company’s stock.
Analyst Ratings Changes
A number of equities research analysts have issued reports on AVTR shares. Robert W. Baird cut their price target on Avantor from $18.00 to $15.00 and set an “outperform” rating for the company in a research note on Monday, August 4th. Royal Bank Of Canada cut their price target on Avantor from $20.00 to $17.00 and set an “outperform” rating for the company in a research note on Monday, August 4th. Jefferies Financial Group reiterated a “hold” rating on shares of Avantor in a research note on Friday, August 1st. Stifel Nicolaus set a $12.00 price target on Avantor and gave the stock a “hold” rating in a research note on Monday, August 4th. Finally, Wells Fargo & Company cut their price target on Avantor from $19.00 to $16.00 and set an “overweight” rating for the company in a research note on Monday, August 4th. Seven investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $15.65.
Get Our Latest Stock Report on AVTR
Avantor Profile
Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.
Read More
- Five stocks we like better than Avantor
- What is a SEC Filing?
- General Dynamics Hits New Highs: Why It Might Keep Climbing
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Nike’s Turnaround: If the Shoe Fits, Buy It!
- Why Invest in High-Yield Dividend Stocks?
- NVIDIA Breaks Out to New Highs: What Comes Next?
Want to see what other hedge funds are holding AVTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avantor, Inc. (NYSE:AVTR – Free Report).
Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.